@MFellermeyer

Final year PhD student focusing on cancer immunotherapy and antibody engineering @DavisLab_Oxford @UniofOxford.

Joined March 2023
  • Tweets5
  • Following39
  • Followers30
Martin Fellermeyer retweeted
MRC TIDU@MRC_TIDU13 Feb 2024
NEW: @ImmunityCP study from the @DavisLab_Oxford, @CornallLab and @KlenermanLab uncovers how antibodies trigger immune receptors & provides a framework for designing better therapeutic antibodies for cancer & autoimmune diseases. Read the full story here: bit.ly/498KFEB
An illustration showing the surfaces of two cells coming together, with one at the top of the image and one at the bottom. A purple molecule protruding downwards from the top 'cell' and a green molecule protruding upwards from the bottom 'cell' are both bound to the same yellow molecule in the middle of the image. A red molecule protrudes downwards from the surface of the bottom cell. There is a large blue molecule to the right of the image that can't 'fit' between the two 'cells' where the interaction with the yellow molecule is occurring.

ALT An illustration showing the surfaces of two cells coming together, with one at the top of the image and one at the bottom. A purple molecule protruding downwards from the top 'cell' and a green molecule protruding upwards from the bottom 'cell' are both bound to the same yellow molecule in the middle of the image. A red molecule protrudes downwards from the surface of the bottom cell. There is a large blue molecule to the right of the image that can't 'fit' between the two 'cells' where the interaction with the yellow molecule is occurring.

14
27
6,344
Martin Fellermeyer retweeted
Edward Jenkins@DrEdJenks18 Jul 2023
Got a big itch to study T-cell exhaustion!!?? Our review has got your back! We include: 🙆The latest updates in exhaustion🙆 🧪In vivo/vitro models of exhaustion🧪 📊How to best verify in vitro exhausted T cells📊 📈The future of in vitro approaches📈 doi.org/10.1093/oxfimm/iqad0…

The current state and future of T-cell exhaustion research

Abstract. ‘Exhaustion’ is a term used to describe a state of native and redirected T-cell hypo-responsiveness resulting from persistent antigen exposure du

academic.oup.com
1
4
18
3,697
Thanks to the WIMM Postdoc Association for organising this symposium!
MRC WIMM@MRC_WIMM20 Jun 2023
Congratulations to the winners of the audience-voted awards at the @MRC_WIMM Postdoc Symposium yesterday: 🎉Best Scientific Report: Andrew McIntyre (@ChakravertyLab) 🌟Best Introductory Flash Talk: @MFellermeyer (@DavisLab_Oxford) ⚡️Runner Up: Li-Hsin Chang (@jdavieslab)
photo of two men and a woman smiling in front of some buildings and greenery

ALT photo of two men and a woman smiling in front of some buildings and greenery

11
321
Researchers at @DavisLab_Oxford investigate the potential of a new combination #immunotherapy of #nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a #CD200R blocker Explore their results in mouse models for colorectal & lung #cancer ➡️bit.ly/3Madlmm
3
1
5
1,719
Very pleased to have my first PhD publication published in @IMTadvances. Using humanised mice we trialled the combination immunotherapy of nivolumab and OX108 (a CD200R blocker) in two tumour models. @DavisLab_Oxford @CornallLab @MRC_HIU @MRC_WIMM @RDMOxford
Immunotherapy Advances Journal@IMTadvances31 Mar 2023
Our latest article explores the potential of a combination #immunotherapy comprising #Nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a CD200R antagonist, in mouse models for colorectal & lung #cancer Explore the results ➡️bit.ly/3nCdUwU
1
5
1
23
3,914
Load more